Press Releases
Ionis Pharmaceuticals' CEO, Dr. Stanley Crooke, Receives Lifetime Achievement Award from the Oligonucleotide Therapeutics Society
"The OTS Lifetime Achievement Award is reserved for a distinguished individual who has made remarkable contributions to the advancement of the field of oligonucleotide sciences. As a renowned leader in the field, Dr. Crooke is exceptionally well-deserving of this award," said Dr.
Dr. Crooke has demonstrated, throughout his career, his commitment to discovering and developing novel medicines for patients with high unmet medical need. In 1989, Dr. Crooke founded
"I am deeply grateful to be recognized by my peers at the
ABOUT
Dr. Crooke is recognized as one the world's foremost experts on antisense technology. In addition to his responsibilities as the CEO and chairman of the board of directors at Ionis, he leads an active research lab focused on advancing antisense drug technology through the elucidation of its underlying molecular mechanisms. His publications include over 450 scientific papers and he has edited 21 books.
Dr. Crooke started his industry career at
Dr. Crooke has also supported the creation and growth of a number of companies based on Ionis' technology, including Akcea, Regulus, Ibis and others. He has served as a board member of 22 biotechnology and scientific companies and is currently a member of the board of directors of the
ABOUT
Ionis is the leading company in RNA-targeted drug discovery and development focused on developing drugs for patients who have the highest unmet medical needs, such as those patients with severe and rare diseases. Using its proprietary antisense technology, Ionis has created a large pipeline of first-in-class or best-in-class drugs, with over a dozen drugs in mid- to late-stage development. Drugs currently in Phase 3 development include volanesorsen, a drug Ionis is developing and plans to commercialize through its wholly owned subsidiary, Akcea Therapeutics, to treat patients with either familial chylomicronemia syndrome or familial partial lipodystrophy; IONIS-TTRRx, a drug Ionis is developing with GSK to treat patients with all forms of TTR amyloidosis; and nusinersen, a drug Ionis is developing with Biogen to treat infants and children with spinal muscular atrophy. Ionis' patents provide strong and extensive protection for its drugs and technology. Additional information about Ionis is available at www.ionispharma.com.
IONIS' FORWARD-LOOKING STATEMENT
This press release includes forward-looking statements regarding the therapeutic and commercial potential of Ionis' technologies and products in development, including nusinersen, IONIS-TTRRx and volanesorsen. Any statement describing Ionis' goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs. Ionis' forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements. Although Ionis' forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Ionis. As a result, you are cautioned not to rely on these forward-looking statements. These and other risks concerning Ionis' programs are described in additional detail in Ionis' annual report on Form 10-K for the year ended
In this press release, unless the context requires otherwise, "Ionis," "Company," "we," "our," and "us" refers to
Ionis Pharmaceuticals™ is a trademark of
Logo - http://photos.prnewswire.com/prnh/20151221/317736LOGO
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/ionis-pharmaceuticals-ceo-dr-stanley-crooke-receives-lifetime-achievement-award-from-the-oligonucleotide-therapeutics-society-300335193.html
SOURCE
D. Wade Walke, Ph.D., Vice President, Corporate Communications and Investor Relations, 760-603-2741